RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+8.44%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$5.25B
AUM Growth
+$5.25B
(+9.4%)
Cap. Flow
+$313M
Cap. Flow
% of AUM
5.95%
Top 10 Holdings %
Top 10 Hldgs %
53.61%
Holding
70
New
10
Increased
19
Reduced
1
Closed
8
Top Buys
| 1 |
Bruker
BRKR
|
$131M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$103M |
| 3 |
Intuitive Surgical
ISRG
|
$58.1M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$52.3M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$51.2M |
Top Sells
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$351M |
| 2 |
Ventyx Biosciences
VTYX
|
$46.5M |
| 3 |
Apyx Medical
APYX
|
$8.15M |
| 4 |
ALLK
Allakos
ALLK
|
$5.9M |
| 5 |
Castle Biosciences
CSTL
|
$5.87M |
Sector Composition
| 1 | Healthcare | 99.97% |
| 2 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Madrigal Pharmaceuticals
MDGL
$9.7B
| $51.2M | 0.97% |
+221,562
| New | +$51.2M |
|
27
Stoke Therapeutics
STOK
$1.08B
| $46.7M | 0.89% |
4,390,558
| – | – |
|
28
Tarsus Pharmaceuticals
TARS
$2.44B
| $46M | 0.88% |
2,548,125
| – | – |
|
|
AXNX
29
DELISTED
Axonics, Inc. Common Stock
AXNX
| $44.7M | 0.85% |
884,974
| – | – |
|
30
Orchestra BioMed
OBIO
$147M
| $39.3M | 0.75% |
5,620,640
+502,133
| +10% | +$3.51M |
|
31
scPharmaceuticals
SCPH
$296M
| $33.6M | 0.64% |
3,297,843
| – | – |
|
|
CUTR
32
DELISTED
Cutera, Inc.
CUTR
| $27.9M | 0.53% |
1,846,596
| – | – |
|
33
Merus
MRUS
$5.04B
| $27.7M | 0.53% |
+1,050,893
| New | +$27.7M |
|
34
GH Research
GHRS
$870M
| $25.7M | 0.49% |
2,168,957
| – | – |
|
35
MoonLake Immunotherapeutics
MLTX
$3.78B
| $25.5M | 0.49% |
500,000
| – | – |
|
36
Insmed
INSM
$30.3B
| $21.1M | 0.4% |
+1,000,000
| New | +$21.1M |
|
|
SLRN
37
DELISTED
ACELYRIN
SLRN
| $20.4M | 0.39% |
+978,310
| New | +$20.4M |
|
38
Fulcrum Therapeutics
FULC
$353M
| $20M | 0.38% |
6,064,123
+552,284
| +10% | +$1.82M |
|
39
Maravai LifeSciences
MRVI
$341M
| $19.1M | 0.36% |
+1,532,685
| New | +$19.1M |
|
40
PMV Pharmaceuticals
PMVP
$82.1M
| $19M | 0.36% |
3,029,551
+30,453
| +1% | +$191K |
|
41
Guardant Health
GH
$8.11B
| $17.9M | 0.34% |
500,887
+70,000
| +16% | +$2.51M |
|
42
Outset Medical
OM
$245M
| $17.7M | 0.34% |
53,911
| – | – |
|
43
Viking Therapeutics
VKTX
$3.02B
| $16.2M | 0.31% |
1,000,000
| – | – |
|
44
Mineralys Therapeutics
MLYS
$1.94B
| $15.7M | 0.3% |
922,100
| – | – |
|
45
Roivant Sciences
ROIV
$8.6B
| $15.7M | 0.3% |
1,552,717
| – | – |
|
|
OLK
46
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $12.3M | 0.23% |
654,612
| – | – |
|
47
Immunic
IMUX
$79.4M
| $10.8M | 0.21% |
4,294,459
| – | – |
|
48
Adicet Bio
ACET
$60.8M
| $10.3M | 0.2% |
4,241,472
| – | – |
|
49
Design Therapeutics
DSGN
$339M
| $9.85M | 0.19% |
+1,563,031
| New | +$9.85M |
|
50
Immatics
IMTX
$662M
| $9.75M | 0.19% |
845,000
| – | – |
|